Senior Manager of Corporate Strategy and Business Operations Group. These are challenging and high impact opportunities with a broad mandate around driving a variety of initiatives and projects related to corporate strategy, strategic planning, business operations, and transformation. The selected individuals will need to work seamlessly across functions and at multiple levels to frame and activate a variety of strategy-related programs and projects at the specific direction of the CEO, other senior executives, and/or the Board of Directors.
Qualified candidates will be expected to appropriately prioritize all on-going and planned activities and represent the team at senior level meetings by providing critical information needed for management to make informed decisions. This role is multi-faceted and dynamic, requiring candidates to have a diversified skill set including strong leadership, the ability to effectively collaborate, and engage in challenging conversations while maintaining a positive outcome. A candidate’s ability to manage such complex programs, motivate cross-functional teams of people who will not have a direct reporting line, and be masters of both written and oral communication, is critical.
- Own specific elements of the annual Corporate Strategic Plan
- Support the development of annual Long Range Financial Plan
- Drive and coordinate cross-functional strategic and functional initiatives and ensure implementation
- Craft and deliver senior level communications around strategic initiatives and related work
- Develop and leverage senior level relationships across functions for the purpose of aligning and ensuring execution
- Capability and Capacity Planning:
- Work with key functions to define the key capabilities that should be developed to achieve the long-term strategic plan
- For each capability, develop long-term detailed capacity forecast
- Work with Corporate Finance to allocate resources to build-out the key capabilities over time
- Corporate Planning:
- Develop and maintain a database of all corporate and functional activities
- Link to resources required for each program and across programs, working wth FP&A
- Managing timelines and resources across functions
- Business Operations:
- Work with the functions to link corporate objectives to functional, program and cross-functional objectives
- Track progress against objectives, and measure and benchmark performance
- Business Transformation:
- Work with senior functional leaders to identify opportunities to increase both the effectiveness and efficiencies in organizational processes
- Prioritize such opportunities and develop time-phased implementation plans
- Monitor implementation progress
- 3+ years of experience post advanced degree
- 1-2 years of management consulting experience with a top-tier firm focused on strategy, operations and transformation topics for pharmaceutical companies
- Advanced degree (Ph.D. or MBA or Masters) from a premier institution
Boston, MA, United States
Some opportunities happen only once in a lifetime – like a job where you have the extraordinary opportunity to change lives. At Alexion, such opportunities arise through our unwavering mission to serve patients and families affected by rare diseases. These patients are our guiding star, and we act with integrity, urgency, and discipline because we know their lives are at stake.
Alexion is a global biopharmaceutical company focused on serving patients and families affected by rare diseases and devastating conditions through the discovery, development and commercialization of life-changing medicines. As a leader in rare diseases for more than 25 years, Alexion has developed and commercializes two approved complement inhibitors to treat patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS), as well as the first and only approved complement inhibitor to treat anti-acetylcholine receptor (AchR) antibody-positive generalized myasthenia gravis (gMG) and neuromyelitis optica spectrum disorder (NMOSD). Alexion also has two highly innovative enzyme replacement therapies for patients with life-threatening and ultra-rare metabolic disorders, hypophosphatasia (HPP) and lysosomal acid lipase deficiency (LAL-D) as well as the first and only approved Factor Xa inhibitor reversal agent. In addition, the company is developing several mid-to-late-stage therapies, including a copper-binding agent for Wilson disease, an anti-neonatal Fc receptor (FcRn) antibody for rare Immunoglobulin G (IgG)-mediated diseases and an oral Factor D inhibitor as well as several early-stage therapies, including one for light chain (AL) amyloidosis, a second oral Factor D inhibitor and a third complement inhibitor. Alexion focuses its research efforts on novel molecules and targets in the complement cascade and its development efforts on the core therapeutic areas of hematology, nephrology, neurology, metabolic disorders and cardiology. Headquartered in Boston, Massachusetts, Alexion has offices around the globe and serves patients in more than 50 countries. Further information about Alexion can be found at: www.alexion.com .